Skip to main content
SpringerLink
Log in

[68 Ga]Ga-FAPI versus [18F]F-FDG in malignant melanoma: complementary or counterpoint?

  • Image of the Month
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Olumi, AF, Grossfeld GD, Hayward SW, Carroll PR, Cunha GR, Hein P, Tlsty TD. (2000). Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium. Breast Cancer Res. 2000; 2(Suppl 1): S.19. https://doi.org/10.1186/bcr138

  2. Hutchenreuther J, Vincent K, Norley C, Racanelli M, Gruber SB, Johnson TM, Fullen DR, Raskin L, Perbal B, Holdsworth DW, Postovit LM, Leask A. Activation of cancer-associated fibroblasts is required for tumor neovascularization in a murine model of melanoma. Matrix Biol. 2018;74:52–61. https://doi.org/10.1016/j.matbio.2018.06.003.

    Article  CAS  PubMed  Google Scholar 

  3. Romano V, Belviso I, Venuta A, Ruocco MR, Masone S, Aliotta F, Fiume G, Montagnani S, Avagliano A, Arcucci A. Influence of tumor microenvironment and fibroblast population plasticity on melanoma growth, therapy resistance and immunoescape. Int J Mol Sci. 2021;22(10):5283. https://doi.org/10.3390/ijms22105283.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, Jager D, Mier W, Haberkorn U. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59(9):1415–22. https://doi.org/10.2967/jnumed.118.210443.

    Article  CAS  PubMed  Google Scholar 

  5. Loktev A, Lindner T, Burger EM, Altmann A, Giesel F, Kratochwil C, Debus J, Marme F, Jager D, Mier W, Haberkorn U. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J Nucl Med. 2019;60(10):1421–9. https://doi.org/10.2967/jnumed.118.224469.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, Debus J, Jäger D, Flechsig P, Altmann A, Mier W, Haberkorn U. 68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60(3):386–92. https://doi.org/10.2967/jnumed.118.215913.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Private Bag X169, Pretoria, 0001, South Africa

    Kgomotso Mokoala, Ismaheel Lawal & Mike Sathekge

  2. Department of Nuclear Medicine, Medical Faculty, University Hospital Duesseldorf, Heinrich Heine University, Düsseldorf, Germany

    Novruzov Emil, Christina Antke & Frederik L. Giesel

  3. Nuclear Medicine Research Infrastructure (NuMeRI), Steve Biko Academic Hospital, Pretoria, South Africa

    Ismaheel Lawal & Mike Sathekge

Authors
  1. Kgomotso Mokoala
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Novruzov Emil
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ismaheel Lawal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christina Antke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Frederik L. Giesel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mike Sathekge
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mike Sathekge.

Ethics declarations

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Approval was granted by the Ethics Committee of University of Pretoria (Nr. 881/2019).

Consent to participate

The patient gave informed consent to using clinical data for research and scientific purposes.

Consent for publication

The patient gave signed consent to using clinical data for scientific purposes. Informed consent was obtained from the patient for publication of his case/report and accompanying images.

Conflict of interest

FLG has a patent application for quinolone-based FAP-targeting agents for imaging and therapy in nuclear medicine and shares of iTheranostics. Furthermore, FLG is a medical advisor for ABX Advanced Biochemical Compound and Telix Pharmaceuticals. The other authors have no relevant financial or non-financial interests to disclose.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Image of the month

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mokoala, K., Emil, N., Lawal, I. et al. [68 Ga]Ga-FAPI versus [18F]F-FDG in malignant melanoma: complementary or counterpoint?. Eur J Nucl Med Mol Imaging 49, 2445–2446 (2022). https://doi.org/10.1007/s00259-022-05702-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-022-05702-2

Search

Navigation